Stock Track | Bio-Rad Laboratories Plunges 12.8% in Pre-Market on Analyst Downgrade Following Earnings Miss and Weak Outlook

Stock Track

Feb 13

Bio-Rad Laboratories' stock experienced a sharp pre-market plunge of 12.80% on Friday, extending losses from the previous session.

The decline follows a significant analyst action, with Jefferies cutting its price target on the life sciences company to $280 from $325. This downgrade comes in response to Bio-Rad's recent fourth-quarter earnings report, which fell short of expectations, and its conservative guidance for the coming year.

The company reported adjusted earnings per share of $2.51 for the quarter, missing the consensus estimate and representing a year-over-year decline. Furthermore, management issued a weak outlook for fiscal year 2026, projecting minimal revenue growth and citing challenges including geopolitical uncertainty and constrained funding in the academic and biotech sectors, which has already impacted its Life Science segment sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1157085030"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157085030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157085030?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157085030","market":"nz","top_or_hot":-1,"title":"Stock Track | Bio-Rad Laboratories Plunges 12.8% in Pre-Market on Analyst Downgrade Following Earnings Miss and Weak Outlook","media":"Stock Track","content":"<p>Bio-Rad Laboratories' stock experienced a sharp pre-market plunge of 12.80% on Friday, extending losses from the previous session.</p><p>The decline follows a significant analyst action, with Jefferies cutting its price target on the life sciences company to $280 from $325. This downgrade comes in response to Bio-Rad's recent fourth-quarter earnings report, which fell short of expectations, and its conservative guidance for the coming year.</p><p>The company reported adjusted earnings per share of $2.51 for the quarter, missing the consensus estimate and representing a year-over-year decline. Furthermore, management issued a weak outlook for fiscal year 2026, projecting minimal revenue growth and citing challenges including geopolitical uncertainty and constrained funding in the academic and biotech sectors, which has already impacted its Life Science segment sales.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bio-Rad Laboratories Plunges 12.8% in Pre-Market on Analyst Downgrade Following Earnings Miss and Weak Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bio-Rad Laboratories Plunges 12.8% in Pre-Market on Analyst Downgrade Following Earnings Miss and Weak Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-13 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bio-Rad Laboratories' stock experienced a sharp pre-market plunge of 12.80% on Friday, extending losses from the previous session.</p><p>The decline follows a significant analyst action, with Jefferies cutting its price target on the life sciences company to $280 from $325. This downgrade comes in response to Bio-Rad's recent fourth-quarter earnings report, which fell short of expectations, and its conservative guidance for the coming year.</p><p>The company reported adjusted earnings per share of $2.51 for the quarter, missing the consensus estimate and representing a year-over-year decline. Furthermore, management issued a weak outlook for fiscal year 2026, projecting minimal revenue growth and citing challenges including geopolitical uncertainty and constrained funding in the academic and biotech sectors, which has already impacted its Life Science segment sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIO","symbol_name":"Bio Rad实验室","start_time":0,"source_url":"","article_id":"1157085030","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157085030","pubTimestamp":1770987811,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Bio-Rad Laboratories' stock experienced a sharp pre-market plunge of 12.80% on Friday, extending losses from the previous session.The decline follows a significant analyst action, with Jefferies...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIO":"Bio Rad实验室"},"translate_title":"个股追踪|Bio-Rad Laboratories盘前暴跌12.8%，因盈利未达预期且前景疲弱，分析师下调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":1},"content_text":"Bio-Rad Laboratories' stock experienced a sharp pre-market plunge of 12.80% on Friday, extending losses from the previous session.The decline follows a significant analyst action, with Jefferies cutting its price target on the life sciences company to $280 from $325. This downgrade comes in response to Bio-Rad's recent fourth-quarter earnings report, which fell short of expectations, and its conservative guidance for the coming year.The company reported adjusted earnings per share of $2.51 for the quarter, missing the consensus estimate and representing a year-over-year decline. Furthermore, management issued a weak outlook for fiscal year 2026, projecting minimal revenue growth and citing challenges including geopolitical uncertainty and constrained funding in the academic and biotech sectors, which has already impacted its Life Science segment sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}